Navigation Links
Permeon reveals discovery of Intraphilins as new approach to intracellular biologic drugs
Date:7/29/2011

Permeon Biologics, a biopharmaceutical company pioneering a novel class of intracellular protein biologics, today announced the discovery of an entirely new class of naturally occurring human supercharged proteins called Intraphilins. The sequence and structure of these naturally supercharged human proteins enable biologic drugs to penetrate and function inside of mammalian cells. This new class of proteins is the foundation of Permeon Biologics' novel Intraphilin Technology Platform and provides an innovative approach to develop intracellular protein biologic drugs, such as intracellular monoclonal antibodies and enzyme replacement therapies. Intraphilins enable functional proteins to act inside cells to treat disease, impacting over 1,500 intracellular target proteins currently considered undruggable with available technologies.

The data were published online today in the journal Chemistry & Biology in a seminal paper by David R. Liu, Ph.D., professor of chemistry and chemical biology at Harvard University and investigator at the Howard Hughes Medical Institute, and his colleagues. The findings represent natural scaffolds for developing potent human intracellular biologic drugs, and also raise the possibility that some of these supercharged proteins may penetrate cells as part of their native biological functions. The ability of human Intraphilins to penetrate cells to enable intracellular protein biologics has not been previously reported.

"The data show that naturally supercharged Intraphilin proteins already exist within the human body and can enable the delivery of protein biologics into mammalian cells in vivo," said Dr. Liu, Permeon's scientific founder and scientific advisory board chairman. "Intraphilins are now being developed as a new class of human protein therapeutics to access previously undruggable intracellular target proteins and pathways."

The study sought to determine if this class of proteins could provide a natural platform for intracellular protein biologics in vivo. Dr. Liu and his colleagues tested the ability of Intraphilins to enable active enzymes in adult mice to function in cells of three tissues of therapeutic interest the retina, pancreas and white adipose tissues. Intraphilins were fused to Cre recombinase, an enzyme that mediates DNA splicing inside the nuclei of cells, then injected into the mice.

Following a post-injection incubation period, each Intraphilin-Cre recombinase fusion protein tested exhibited DNA splicing activity in the nuclei of living cells in each of the tissues tested. These study results collectively establish that Intraphilins enable protein biologics to function inside a variety of living mammalian tissues in vivo. The paper shows that Intraphilin-Cre-injected retinae exhibited large areas of recombined cells in the eyes of treated mice. In contrast, retinae injected with Cre recombinase protein by itself did not show activity in vivo, highlighting that protein biologics are typically unable to enter cells. Of importance, the Intraphilins tested were able to mediate internalization of fused proteins with up to 40-fold higher potency than cell penetrating peptides, which have been used previously to develop intracellular biologics.

"This potent ability to target and treat the source of disease within the cell cytoplasm and other intracellular compartments holds promise to address a vast new spectrum of intracellular disease targets," said Alex Franzusoff, Ph.D., president and board director of Permeon Biologics. "First-generation approaches to intracellular biologics, such as cell-penetrating peptides, have not realized their full potential due to limited uptake of larger macromolecules into cells and limited tolerability. This paper shows for the first time that we can leverage natural human proteins to enable intracellular protein biologics, such as humanized intracellular monoclonal antibodies, to address clinically important targets of interest which were previously undruggable."


'/>"/>

Contact: Michele Rozen
617-730-8284
Pure Communications Inc.
Source:Eurekalert

Related biology technology :

1. Whole sequence variation map reveals insight into evolutionary studies of rhesus macaque
2. New research reveals soil microbes accelerate global warming
3. DNA Sequencing Data Reveals New Hybrid E. coli Strain is Cause of German Outbreak
4. Combo method reveals cells signal systems
5. LasikPlusĀ® Research Reveals Excellent Results From Modern LASIK
6. Study of 90 animals thigh bones reveals how they can efficiently carry loads
7. Nanoscale probe reveals interactions between surfaces and single molecules
8. Major disease-vector mosquito reveals the secrets of its immune system
9. Health 2.0 Reveals the Winners of the 2010 Developer Challenge
10. Elsevier Survey Reveals Researchers Ready to Push Scientific Search and Discovery to the Next Level
11. Unprecedented look at oxide interfaces reveals unexpected structures on atomic scale
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from Austria, Hungary, ... be a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has ... it now. , Biomarkers are components in the blood, tissue or body ...
(Date:6/27/2016)... Hill, N.C. (PRWEB) , ... June 27, 2016 ... ... U.S. commercial operations for Amgen, will join the faculty of the University ... serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a ...
(Date:6/24/2016)...  Regular discussions on a range of subjects including policies, ... entities said Poloz. Speaking at a lecture to ... he pointed to the country,s inflation target, which is set ... "In certain areas there needs ... economic goals, why not sit down and address strategy together?" ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
Breaking Biology News(10 mins):